You are now leaving NeulastaHCP.com

Please be aware that the sponsors of this site are not responsible for content on the site you are about to enter.

Return to Previous Page Continue to External Site

Dose Modification: Non-Hodgkin's Lymphoma

Neutropenia may impact chemotherapy delivery in patients with non-Hodgkin's lymphoma (NHL). In the curative setting, patients with NHL may experience dose delays and dose reductions. In fact, a study of NHL patients being treated with chemotherapy found that nearly a quarter of patients in the study experienced dose delays of ≥7 days. In the same study, 40% of patients experienced dose reductions of ≥15%.1

—Adapted from Lyman G, et al. J Clin Oncol. 2004.

Neutropenia (both grade 3-4 and febrile) was the most frequent cause of chemotherapy dose delays and dose reductions.2

—Adapted from Picozzi V, et al. Oncology. 2001.

References

  1. Lyman G, Dale D, Friedberg J, Crawford J, Fisher R. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin‘s lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302-4311.
  2. Picozzi V, Pohlman B, Morrison V, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin‘s lymphoma. Oncology. 2001;15:1296-1306.